- Report
- September 2021
- 126 Pages
Global
From €10698EUR$10,995USD£9,164GBP
- Report
- August 2021
- 45 Pages
Global
From €3887EUR$3,995USD£3,330GBP
- Clinical Trials
- May 2020
- 450 Pages
Global
From €2432EUR$2,500USD£2,084GBP
- Drug Pipelines
- June 2020
- 795 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Drug Pipelines
- October 2018
- 92 Pages
Global
From €3405EUR$3,500USD£2,917GBP
- Report
- June 2023
- 110 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- December 2022
- 157 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Report
- May 2022
- 52 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Report
- February 2024
- 180 Pages
Global
From €5350EUR$5,499USD£4,583GBP
Neuroendocrine carcinoma (NEC) is a rare type of cancer that affects the neuroendocrine system, which is responsible for the production of hormones. It is a type of cancer that is often difficult to diagnose and treat. Treatment options for NEC include surgery, chemotherapy, radiation therapy, and targeted therapies. Oncology drugs are used to treat NEC, and they can be used alone or in combination with other treatments. These drugs can help to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of recurrence.
The Neuroendocrine Carcinoma market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of NEC, the development of new treatments, and the increasing availability of targeted therapies. Companies in the market include Novartis, Pfizer, Merck, AstraZeneca, and Roche. Show Less Read more
